FindTrial
Sign In

Evaluation of NT-ProBNP marker to predict the cardiovascular risk in individuals with type 2 diabetes.

NT-ProBNP: a novel predictor of cardiovascular risk in type 2 diabetes - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/12/060795
Enrollment
302
Registered
2023-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Roche Diagnostics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus patients with or without cardiovascular disease of either gender.

Exclusion criteria

Exclusion criteria: Subjects who had cancer and renal dysfunction, Pregnancy, Subjects with valvular, rheumatic, and congenital heart disease

Design outcomes

Primary

MeasureTime frame
NT-ProBNP, fasting glucose, HbA1c, HDL, triglycerides, total cholesterol, LDL, micro-albuminuria, and creatinineTimepoint: Baseline—

Secondary

MeasureTime frame
Risk stratification assessment for CVD using risk toolsTimepoint: baseline—

Countries

India

Contacts

Public ContactSahana Shetty

Manipal Academy of Higher Education

sahana.shetty@manipal.edu9944745014

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026